These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 9750510

  • 1. [Clinical usefulness of blood PICP, PINP and ICTP concentrations as bone metastasis markers in prostate cancer patients].
    Kobayashi Y, Tokue A.
    Nihon Rinsho; 1998 Aug; 56(8):2072-6. PubMed ID: 9750510
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
    Koizumi M, Takahashi S, Ogata E.
    Anticancer Res; 2003 Aug; 23(5b):4095-9. PubMed ID: 14666607
    [Abstract] [Full Text] [Related]

  • 8. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
    Zissimopoulos A, Stellos K, Matthaios D, Petrakis G, Parmenopoulou V, Babatsikou F, Matthaiou E, Theodosiadou E, Hountis P, Koutis C.
    J BUON; 2009 Aug; 14(3):463-72. PubMed ID: 19810140
    [Abstract] [Full Text] [Related]

  • 9. Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach.
    Koopmans N, de Jong IJ, Breeuwsma AJ, van der Veer E.
    J Urol; 2007 Sep; 178(3 Pt 1):849-53; discussion 853; quiz 1129. PubMed ID: 17631330
    [Abstract] [Full Text] [Related]

  • 10. [Studies of type I collagen related substances as bone metastatic markers of prostate carcinoma with special regard to serum carboxyterminal propeptide of type. I. Procollagen (PICP), cross-linked carboxyterminal telopeptide of type I collagen (ICTP) and Urinary deoxypyridinoline levels].
    Imai T, Honda M, Maeda S, Hosoya Y, Arai T, Sumi S, Umeda H, Yano M, Koga F, Arai K, Yoshida K.
    Nihon Hinyokika Gakkai Zasshi; 1998 Apr; 89(4):484-91. PubMed ID: 9597867
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Serum levels of carboxyterminal propeptide of type I procollagen (PICP), cross-linked carboxyterminal telopeptide region of type I collagen (ICTP) and carboxyterminal parathyroid hormone-related protein (C-PTHrP) in hematological malignancies with bone lesions and hypercalcemia].
    Tanaka K, Shiraishi K, Sakamoto A, Jojima H, Masuchi K, Okubo Y, Tanaka M, Fuzimatsu Y, Fukahori S, Osabe S, Imamura Y, Honda J, Oizumi K.
    Rinsho Ketsueki; 1998 Apr; 39(4):273-80. PubMed ID: 9597894
    [Abstract] [Full Text] [Related]

  • 15. Serum type I collagen degradation markers, ICTP and CrossLaps, are factors for poor survival in lung cancer.
    Ylisirniö S, Sassi ML, Risteli J, Turpeenniemi-Hujanen T, Jukkola A.
    Anticancer Res; 1999 Apr; 19(6C):5577-81. PubMed ID: 10697621
    [Abstract] [Full Text] [Related]

  • 16. Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer.
    Koizumi M, Yonese J, Fukui I, Ogata E.
    J Urol; 2002 Apr; 167(4):1863-6. PubMed ID: 11912449
    [Abstract] [Full Text] [Related]

  • 17. Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer.
    Aktas B, Kasimir-Bauer S, Lehmann N, Kimmig R, Tewes M.
    Oncol Rep; 2013 Jul; 30(1):441-7. PubMed ID: 23604361
    [Abstract] [Full Text] [Related]

  • 18. Preoperative high type I collagen degradation marker ICTP reflects advanced breast cancer.
    Keskikuru R, Kataja V, Kosma VM, Eskelinen M, Uusitupa M, Johansson R, Risteli L, Risteli J, Jukkola A.
    Anticancer Res; 1999 Jul; 19(5C):4481-4. PubMed ID: 10650796
    [Abstract] [Full Text] [Related]

  • 19. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D, Siepmann S, Geppert R, Wernecke KD, Possinger K, Lüftner D.
    Anticancer Res; 2007 Jul; 27(4A):1853-62. PubMed ID: 17649784
    [Abstract] [Full Text] [Related]

  • 20. Postoperative PINP in serum reflects metastatic potential and poor survival in node-positive breast cancer.
    Jukkola A, Bloigu R, Holli K, Joensuu H, Valavaara R, Risteli J, Blanco G.
    Anticancer Res; 2001 Jul; 21(4B):2873-6. PubMed ID: 11712779
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.